• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bull Horn Holdings Corp. (Amendment)

    11/7/22 2:13:50 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BHSE alert in real time by email
    SC 13G/A 1 lenapharma_13g.htm AMENDMENT 5

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (AMENDMENT N0. 5)1

     

    Coeptis Therapeutics Holdings, Inc.

     

    (Name of Issuer)

     

     

    Common Shares, $0.0001 par value per share

     

    (Title of Class of Securities)

     

     

    19207A108

     

    (CUSIP Number)

     

     

    October 28, 2022

     

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [  ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [  ] Rule 13d-1(d)

     

            1  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.)

     

     

       

     

     

    CUSIP No. 629709205
    1. NAMES OF REPORTING PERSONS

    Lena Pharma, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [  ]
    (b) [  ]
    3.

    SEC USE ONLY

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Pennsylvania
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.    SOLE VOTING POWER 1,431,691
    6.    SHARED VOTING POWER 0
    7.    SOLE DISPOSITIVE POWER 1,431,691
    8.    SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,431,691
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.33%
    12. TYPE OF REPORTING PERSON

    OO
           

     

     2 

     

     

    Item 1.   
       (a) Name of Issuer
    Coeptis Therapeutics Holdings, Inc.
     (b) Address of Issuer’s Principal Executive Offices
    105 Bradford Rd, Suite 420, Wexford, Pennsylvania 15090
    Item 2.   
     (a) Name of Person Filing
    Lena Pharma, LLC
     (b) Address of Principal Business Office or, if None, Residence

    470 Mohawk Circle, Stoystown, PA 15563

     (c) Citizenship
    Pennsylvania limited liability company
     (d) Title of Class of Securities
    Common Shares, $0.0001 par value per share
     (e) CUSIP Number:  19207A108

     

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) [  ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
      (b) [  ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) [  ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) [  ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) [  ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
      (f) [  ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
      (g) [  ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
      (h) [  ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) [  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) [  ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1

     

      (a) Amount Beneficially Owned:
      1,431,691
      (b) Percent of Class:
      7.34%
      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote 1,431,691
      (ii) shared power to vote or to direct the vote 0
      (iii) sole power to dispose or to direct the disposition of 1,431,691
      (iv) shared power to dispose or to direct the disposition of 0

     

     

     

     3 

     

     

    Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable.
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    Not Applicable.

     

     

     

     4 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      November 7, 2022
      (Date)
       
      /s/ Lena Kuchera
      (Signature)
       
      Lena Kuchera, Manager
      (Name/Title)
       

     

     

     

     

     

     

     5 

     

    Get the next $BHSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHSE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BHSE
    SEC Filings

    View All

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:17:01 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:15:23 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/1/24 5:28:10 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BHSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BHSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)

    3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:01:21 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/9/24 5:32:29 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

    Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq G

    10/31/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

    SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

    9/21/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

    Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial

    5/17/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bull Horn Holdings Corp.

    SC 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/14/24 3:32:56 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bull Horn Holdings Corp. (Amendment)

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/6/23 4:25:12 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Bull Horn Holdings Corp.

    SC 13D - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/7/22 4:10:32 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care